This announcement is a separate document:
浙江海正药业股份有限公司监事会对《董事会关于公司2023年度财务报告非标准审计意见涉及事项的专项说明》的意见
Opinions of the Supervisory Board of Zhejiang Haizheng Pharmaceutical Co., Ltd. on the “Special Instructions of the Board of Directors on Matters Involving Non-standard Audit Opinions on the Company's 2023 Financial Report”
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.